Search

Displaying results 901 - 910 of 4344 in total
  1. Drug

    Olopatadine

    go.drugbank.com/drugs/DB00768
    Approved

    Olopatadine is a selective histamine H1 antagonist and mast cell stabilizer that works by attenuating inflammatory and allergic reactions. … [L6790] Olopatadine works by blocking the effects of histamine, which is a primary inflammatory mediator that causes inflammatory and allergic reactions.

  2. Drug

    Turoctocog alfa

    go.drugbank.com/drugs/DB09109
    Approved

    [A31504] It was developped by Novo Nordisk and FDA approved in October 16, 2013.[L1104]

  3. Drug

    Dapagliflozin

    go.drugbank.com/drugs/DB06292
    ApprovedInvestigational

    [A261601] Dapagliflozin was originally approved by the FDA on Jan 08, 2014, to improve glycemic control in adults with type 2 diabetes in conjunction with diet and exercise. … [A261596] When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosuria

    Mixtures: XIGDUO XR TABLETS 10MG/500MG, XIGDUO XR TABLETS 10MG/1000MGProducts: FORXIGA TABLET 10mg, FORXIGA 10MG FILM-COATED TABLET
  4. Drug

    Clavulanic acid

    go.drugbank.com/drugs/DB00766
    ApprovedInvestigationalVet approved

    Clavulanic acid is a beta-lactamase inhibitor that is frequently combined with [Amoxicillin] or [Ticarcillin] to fight antibiotic resistance by preventing their degradation by beta-lactamase enzymes, broadening

    Mixtures: Amoxicillin/Clavulansäure Astro 500 mg/100 mg Pulver zur Herstellung einer Injektions- oder Infusionslösung, Amoxicillin/Clavulansäure Astro 1000 mg/200 mg Pulver zur Herstellung einer Injektions- oder Infusionslösung
  5. Drug

    Enflurane

    go.drugbank.com/drugs/DB00228
    ApprovedVet approvedWithdrawn

    Enflurane is a halogenated inhalational anesthetic initially approved by the FDA in 1972. Since this date, it has been withdrawn from the US market.

  6. Drug

    Etrasimod

    go.drugbank.com/drugs/DB14766
    ApprovedInvestigational

    [A261831] Etrasimod was approved on October 13, 2023, by the FDA under the brand name VELSIPITY for the treatment of adults with moderately to severely active ulcerative colitis.

  7. Drug

    Omadacycline

    go.drugbank.com/drugs/DB12455
    ApprovedInvestigational

    a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent infections caused by … gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), and by gram-negative, atypical and anaerobic bacteria, including those resistant to currently available classes of antibiotics

  8. Drug

    Disulfiram

    go.drugbank.com/drugs/DB00822
    ApprovedInvestigational

    It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. … It acts by inhibiting aldehyde dehydrogenase.

  9. Drug

    Baclofen

    go.drugbank.com/drugs/DB00181
    ApprovedInvestigational

    Although originally designed in 1962 to treat epilepsy, baclofen was not effective in treating this condition but instead was shown to reduce spasticity in selected patients. … [A245338] Baclofen was reintroduced in 1971 as a treatment for spasticity and was later approved by the FDA in 1977.

    Products: Tab 20mg, LIORESAL 10MG
  10. Drug

    Etuvetidigene Autotemcel

    go.drugbank.com/drugs/DB17593
    ApprovedInvestigational

    [L54693] WAS is a rare X-linked disorder caused by a mutation in the gene encoding the WAS protein, leading to a compromised immune system. … [L54698] First approved by the FDA on December 9, 2025, etuvetidigene autotemcel is used to treat Wiskott–Aldrich syndrome (WAS) in selected pediatric and adult patients.